Wu Wei, Wan Jun, Xia Ruixiang, Huang Zhenqi, Ni Jing, Yang Mingzhen
Department of Hematology, The First Affiliated Hospital of Anhui Medical University Hefei, China.
Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University Hefei, China.
Int J Clin Exp Pathol. 2015 Aug 1;8(8):9133-9. eCollection 2015.
B cell lymphoma (BCL) has a higher degree of malignancy and complicated pathogenic mechanism. Regulatory T cells (Treg cells) are known to exert certain immune suppression functions, in addition to immune mediating effects. Recent studies have revealed the role of Treg cells in pathogenesis and progression of multiple malignant tumors. This study therefore investigated the functional role and related mechanism of Treg cells in BCL. A cohort of thirty patients who were diagnosed with BCL in our hospital between January 2013 and December 2014. Another thirty healthy individuals were recruited. Peripheral blood mononuclear cells (PBMCs) were separated and analyzed for the ratio of CD4+/CD25+ Treg cells. The mRNA expression levels of Foxp3, transforming growth factor (TGF)-β1 and interleukin (IL)-10 genes were quantified by real-time PCR, while their serum levels were determined by enzyme-linked immunosorbent assay (ELISA). Meanwhile all laboratory indexes for patients were monitored during the complete remission (CR) stage. BCL patients significantly elevated ratio of CD4+/CD25+ Treg cells, which were decreased at CR stage. mRNA levels of Foxp3, TGF-β1 and IL-10, in addition to protein levels of TGF-β1 and IL-10 were potentiated in lymphoma patients but decreased in CR patients (P<0.05 in all cases). CD4+/CD25+ Treg cells exert immune suppressing functions in BCL via regulating cytokines, thereby facilitating the pathogenesis and progression of lymphoma.
B细胞淋巴瘤（BCL）具有较高的恶性程度和复杂的致病机制。已知调节性T细胞（Treg细胞）除了具有免疫介导作用外，还发挥一定的免疫抑制功能。最近的研究揭示了Treg细胞在多种恶性肿瘤的发病机制和进展中的作用。因此，本研究调查了Treg细胞在BCL中的功能作用及相关机制。选取2013年1月至2014年12月间在我院确诊为BCL的30例患者。另外招募了30名健康个体。分离外周血单个核细胞（PBMC），分析CD4+/CD25+ Treg细胞的比例。通过实时PCR定量检测Foxp3、转化生长因子（TGF）-β1和白细胞介素（IL）-10基因的mRNA表达水平，同时通过酶联免疫吸附测定（ELISA）测定其血清水平。同时，在完全缓解（CR）阶段监测患者的所有实验室指标。BCL患者CD4+/CD25+ Treg细胞比例显著升高，在CR阶段降低。淋巴瘤患者中Foxp3、TGF-β1和IL-10的mRNA水平以及TGF-β1和IL-10的蛋白水平均升高，但CR患者中降低（所有情况P<0.05）。CD4+/CD25+ Treg细胞通过调节细胞因子在BCL中发挥免疫抑制功能，从而促进淋巴瘤的发病机制和进展。
